Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 294Lymphoma 204Lymphoma, Large B-Cell, Diffuse 168Sarcoma 142Precursor Cell Lymphoblastic Leukemia-Lymphoma 110Hodgkin Disease 85Lymphoma, Non-Hodgkin 79Burkitt Lymphoma 67Lymphoma, Follicular 62Leukemia 58Ovarian Neoplasms 51Triple Negative Breast Neoplasms 50Neoplasms 50Lymphoma, Mantle-Cell 48Multiple Myeloma 47Carcinoma, Hepatocellular 47Neuroblastoma 44Neoplasm Metastasis 42Lymphoma, B-Cell 33Lymphoma, Large-Cell, Anaplastic 31Recurrence 27Lymphoma, T-Cell, Peripheral 27Osteosarcoma 26Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 25Liposarcoma 25Leiomyosarcoma 25Urinary Bladder Neoplasms 23Lymphoma, Large-Cell, Immunoblastic 23Liver Neoplasms 22Endometrial Neoplasms 21

Interventions

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Cyclophosphamide 3pembrolizumab 1fludarabine 1Vincristine 1Prednisone 1Interleukin-21 1Etoposide 1Doxorubicin 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Experimental × Doxorubicin × Clear all
NCT03617432 2018-09-04

Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients

Peking University

Phase 2 Unknown
114 enrolled

Neoplasms, Experimental

Data powered by HemOnc (CC BY 4.0) Colophon âš¡